Verrica Pharmaceuticals Inc (VRCA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $61.16M
Last updated: Nov 17, 2026 at 10:43 AM ET
Verrica Pharmaceuticals Inc (VRCA) Stock Forecast
Analysts expect Verrica Pharmaceuticals (VRCA) to earn -$1.88 per share in the fiscal year ending Dec 31, 2026, on revenue of $24.39M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.14, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 6 | 85.7% |
| Hold | 1 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 60.8%.
- Fiscal year ending Dec 31, 2026
- -$1.88
- EPS consensus, revenue $24.39M
- Fiscal year ending Dec 31, 2027
- -$1.24
- EPS consensus, revenue $39.22M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.88 | -$2.03 to -$1.70 | 4 | $24.39M | $22.60M to $26.60M | 7 |
| Dec 31, 2027 | -$1.24 | -$1.50 to -$0.85 | 4 | $39.22M | $31.20M to $49.70M | 7 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.49 | -$0.67 to -$0.33 | 9 | $7.25M | $6.17M to $8.26M | 9 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.73.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.88 | -$1.97 | -$1.97 | -$2.01 | -$1.73 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.24 | -$1.48 | -$1.48 | -$1.47 | -$1.24 | N/A |
Frequently Asked Questions About VRCA
What is the VRCA stock forecast?
Consensus analyst estimates put Verrica Pharmaceuticals's EPS at -$1.88 for the fiscal year ending Dec 31, 2026, on revenue of $24.39M. The consensus rating from 7 analysts is Buy.
How do analysts rate VRCA stock?
Of 7 analysts covering Verrica Pharmaceuticals, 0 rate it Strong Buy, 6 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VRCA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.88, with estimates from -$2.03 to -$1.70 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.24, with estimates from -$1.50 to -$0.85 from 4 analysts.
What revenue do analysts expect from Verrica Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $24.39M, with estimates from $22.60M to $26.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $39.22M, with estimates from $31.20M to $49.70M.
How many analysts cover VRCA?
7 analysts rate Verrica Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VRCA pages: Overview, Earnings, Forecast, Financials, Competitors